Clinical Trials

A study of more than 205,000 patients with advanced cancer found that physician and practice factors influence clinical trial enrollment, highlighting opportunities to improve access and address participation disparities.

Erik S. Mittra, MD, PhD, highlighted how new PRRT trials may reshape neuroendocrine tumor care, from retreatment and dosimetry to alpha-emitting therapies.

More than 76% of US counties have no TNBC trial, and only 9.8% of rural counties have one vs 47% of metropolitan counties, a new analysis finds.

Rethink trial design with decentralized, community-based models to cut barriers, let patients enroll closer to home, and preserve high-quality safety data.

Learn how community oncologists expand clinical trial access, strengthen safety monitoring, and offer patients nearby investigational therapies and more treatment options.

Theodore Wagener, PhD, of The Ohio State University discusses the design of the phase 2 DREAM LUNG study of psilocybin-assisted therapy for depression in non–small cell lung cancer.

Theodore Wagener, PhD, discusses psychedelics beyond depression in cancer, including neuropathy and chemo brain, and why he expects cancer centers to adopt them.

Theodore Wagener, PhD, discusses an Ohio State feasibility study testing psilocybin-assisted therapy for depression in patients with non–small cell lung cancer.

Sarah Premji, MD, of Sarah Cannon Research Institute, discusses community trial access, biomarker-driven drug development, and key breast cancer studies to watch.

David DiBardino, MD, explains how a hafnium compound is being tested alongside chemoradiation and durvalumab to address low response rates in locally advanced disease.

Purpose-built, decentralized oncology trials bring new therapies to community clinics, expanding access and showing trials aren’t just a last resort.

The phase 2b VISUALIZE trial found abenacianine identified a clinically significant event in 45% of lung cancer surgeries, says Gavin M. Wright, MBBS, FRACS, PhD.

Oncology leaders weigh how to scale trustworthy AI platforms, align governance, and integrate care-research workflows for real-world adoption.

AI-powered trial screening helps community oncology practices identify eligible patients locally, widening access beyond academic centers and reducing barriers such as distance and logistics.

Agentic AI speeds oncology trial screening by synthesizing records and ranking candidates, while clinicians keep final eligibility and consent decisions.

Cancer trials enroll more women but rarely compare outcomes by sex, leaving safety gaps and urging equity-focused study design.

Agentic AI taps electronic medical records to flag timely oncology trial candidates, fit workflow, cut clinician burden, and boost community practice enrollment.

Agentic AI streamlines oncology decisions and trial matching, cutting administrative load, flagging care gaps, and widening community access to studies.

AstraZeneca is discontinuing the phase 3 eVOLVE-Lung02 trial after finding volrustomig plus chemotherapy unlikely to meet its primary end points in metastatic NSCLC.

An analysis found that postprogression access to effective therapy was associated with smaller OS benefits in targeted therapy trials but not in immunotherapy trials.

City of Hope's Dr Ravi Salgia urges fellow oncologists to refer eligible patients to a new national trial predicting immunotherapy success in NSCLC.

City of Hope's Dr Ravi Salgia explains a new national trial using biomarkers to predict immunotherapy success in advanced non–small cell lung cancer.

A cross-sectional analysis of 52 first-line trials found post-progression access to effective therapy correlated with OS benefit in targeted therapy but not checkpoint blockade.

MD Anderson trials test psilocybin therapy for head and neck cancer patients and survivors, aiming to curb suicide risk and ease treatment trauma.

INVINCIBLE-4 restarts testing intratumoral INT230-6 before neoadjuvant pembrolizumab chemotherapy in early TNBC, aiming to boost pCR while reducing severe adverse effects.

The panel discusses the full multidisciplinary team required to optimize outcomes for patients with ROS1-positive advanced NSCLC: neuro-oncology for brain metastasis management, radiation oncology for CNS and bone disease, palliative care and symptom management specialists from diagnosis, physical therapy and nutrition, social work, and mental health services.

The panel addresses patients who received crizotinib or entrectinib in first line rather than lorlatinib, and who are now progressing.

The panel reinforces that oligo-progression management in ROS1-positive NSCLC requires careful distinction from strategies used in EGFR-mutated NSCLC.

For the patient with a G2032R resistance mutation and intracranial progression, the panel unanimously favors lorlatinib-based therapy in second line based on its known activity against solvent-front mutations and documented CNS penetrance, with median duration of response of approximately 7 to 8 months in this setting.

The second clinical case presents a patient with ROS1 fusion-positive advanced NSCLC who achieved partial response on frontline lorlatinib, maintained for 18 months, before symptomatic and radiographic progression: increasing primary tumor size, new contralateral pulmonary nodules, and brain MRI showing 3 new small intracranial lesions.